Apothecary Pharma recalls compounded tirzepatide and NAD+ vials over sterility concerns
DO
By Daniel Okafor · Regulatory Correspondent
Oct 21 14:46 ETSource: Managed Healthcare Executive
From the source
Read at managedhealthcareexecutive.comApothecary Pharma recalls compounded tirzepatide and NAD+ vials over sterility concerns
